Patent Considerations in Biotech IPOs: Lessons from Hong Kong Chapter 18A Listings 22 May 2026 For most biotech companies, patents are more than just legal rights. They anchor the business and often constitute a leading intangible asset. This is particularly true in the context of a Hong Kong IPO under Chapter 18A of the Listing Rules, a regime introduced in 2018 to give pre-revenue biotech companies access to the public markets. A Different Path to the Public Market Before Chapter 18A, listing applicants in Hong Kong had to meet stringent financial tests, including profitability or revenue thresholds, which effectively excluded biotech companies that typically require years of investment before their first product launch. Recognizing this, HKEX created a tailored pathway for biotech companies to raise funds from public investors. Chapter 18A allows biotech companies without revenue or profit to list, provided they satisfy several criteria. These include having at least one Core Product that has advanced into clinical development, evidence of regulatory engagement, and a sustainable R&D pipeline supported by appropriate funding and governance. Within this framework, applicants must also demonstrate that they hold sufficient intellectual property rights to protect their Core Product and the relevant underlying technologies. In practice, IP is a key part of the overall assessment, in combination with clinical data, regulatory progress, development and manufacturing plans, team capability, and financing. Together, these elements give regulators and investors confidence in the company’s innovation, defensibility, and potential for future revenues. Why IP Matters In a Chapter 18A listing, the patent portfolio serves as a practical indicator of business fundamentals, together with clinical data and regulatory progress. Investors consider whether the science is genuinely novel, whether competitors can design around the patent claims, and whether the company can secure exclusivity during the years that matter the most. The company’s IP strategy helps address these questions. Patents do more than confer rights. They show how thoughtfully management has aligned scientific ambition with commercial reality. A biotech company that demonstrates foresight in building, defending, and extending its patent coverage sends a clear signal that it is both a scientific innovator and a disciplined manager of shareholder value. Themes in IP Due Diligence During IPO During the IPO process, regulators and investors focus on several recurring themes when they review a company’s IP. The first is patent scope and quality. A patent that protects only a single compound or formulation is rarely sufficient. Investors look for layered coverage that includes fallback positions, alternative formulations, and in some cases method of use claims that support the commercial plan. The patent claims must also be strong enough to withstand validity challenges. An ambitious but fragile patent portfolio can be as damaging as one that is too narrow. A second theme is global coverage. Biotech is international by nature, and IPO candidates are assessed on whether their patents align with the markets they intend to serve. A deliberate filing strategy that covers all the relevant markets signals that the company has matched its IP footprint to its market ambitions. Anything less can undermine confidence in the ability to capture value. Patent life is another area of scrutiny. Regulators and investors expect companies to plan for life cycle management through divisional applications, continuation filings, or patent term extensions where available. The most valuable years for a biotech business are those with strong exclusivity. A company that shows foresight in preserving that window is more attractive to the market. Finally, platform technologies receive close attention. Many Chapter 18A issuers are built not around a single drug but around platforms such as gene editing tools or novel drug delivery approaches. These platforms can support multiple pipeline products, but only if the underlying patents create a real fence that deters competitors. If the patent claims are narrow or easy to design around, the promise of the platform may not translate into durable defensibility. Investors will examine whether the patent strategy covers not only the first-generation products but also the broader applications of the platform technologies. Aligning Platforms, Pipelines, and Patents The interaction between a company’s technology platform, its pipeline products, and its patent portfolio is a critical yet sometimes overlooked element of IPO readiness. A platform may yield multiple candidates. The value of the platform depends on the strength of the patents that protect it. If the patent portfolio protects only a specific formulation or a single product, the company risks being limited to one asset. By drafting patent claims that reach the underlying platform more broadly, covering architecture or components, key performance parameters, and methods of use and manufacture, the company can present a platform that is both defensible and expandable. Investors then tend to view later candidates as extensions of a protected base rather than independent projects. The same principle applies across modalities. A portfolio confined to one embodiment appears exposed, while platform level claims complemented by carefully layered product specific filings signal both near term and long term value. The aim is to show that the IP strategy evolves with the science and anticipates the company’s commercial path. Implications for Regional Biotech Companies For biotech companies in Singapore and across Asia, the lessons from Chapter 18A listings are clear. Preparing for an IPO is not just about building the science or advancing clinical trials. It is about building an IP portfolio that can withstand scrutiny from both regulators and sophisticated investors. This means starting early. Reviewing the patent portfolio for scope, coverage, and lifecycle management should happen years before a potential listing. Companies should be asking whether their patents genuinely protect their platforms and products, whether their filings cover the right global markets, and whether they have strategies in place to extend exclusivity at the point of commercialization. Patents in the context of an IPO are not simply legal rights. They are the story investors buy into, the reassurance regulators require, and the foundation upon which future revenues are built. For biotech companies with ambitions to step onto the public stage, the message is simple: if Chapter 18A is on your horizon, the time to align your patent strategy with your technology platforms and pipeline products is now.